Sanofi and AstraZeneca are closing in on EU approval of nirsevimab, their long-acting antibody for the protection of newborns and infants from respiratory syncytial virus (RSV) infections.

The shortfalls became so dire that Sanofi, nirsevimab’s manufacturer, stopped taking new orders for certain doses of the ...

Sanofi bought into the nirsevimab programme in 2017, paying $645 million for marketing rights to the antibody, with AZ retaining the responsibility for developing and manufacturing it. Sobi also ...

Sanofi declined to comment to Pharmaceutical Technology when ... preventative antibody Beyfortus (nirsevimab), developed in partnership with AstraZeneca. Positive financial guidance comes despite ...

vaccine Beyfortus (nirsevimab), developed as part of a partnership with AstraZeneca. Whilst revealing its Q4 2024 results, Sanofi said it is planning to execute a $5.12bn share buyback programme ...

High uptake of RSVpreF vaccine and nirsevimab was observed, with 64% of pregnant individuals and 70% of infants receiving them. Factors such as older maternal age, private insurance, and receipt ...

Sanofi and partner AstraZeneca’s AZN RSV antibody Beyfortus (nirsevimab) recorded sales of €841 million in the fourth quarter, up 107% year over year, driven by higher sales in the United ...

The medication – nirsevimab – is given via injection to infants under 8 months old. Unlike a vaccine, the immunization provides a ready-made supply of antibody protection to babies without ...

Sanofi declined to comment to Pharmaceutical ... preventative antibody Beyfortus (nirsevimab), developed in partnership with AstraZeneca. Positive financial guidance comes despite uncertainty ...